Healthcare Industry News: Onkos Surgical
News Release - October 31, 2016
Onkos Surgical(TM) Receives FDA 510(k) Clearance for ELEOS(TM) Limb Salvage SystemPARSIPPANY, N.J., Oct. 31, 2016 -- (Healthcare Sales & Marketing Network) -- Onkos Surgical, an innovative surgical oncology company founded by Patrick Treacy, Anthony Koblish and 1315 Capital has announced today it has received clearance from the U.S. Food and Drug Administration to market the ELEOS™ Limb Salvage System to treat patients with significant bone loss due to cancer, trauma, or previous surgical procedures.
"Surgical Oncology has been an underserved market for some time," said Patrick Treacy, Founder and CEO. "These surgeons and patients deserve more. With the introduction of the ELEOS Limb Salvage System, we will continue to build on our promise of delivering meaningful innovation in the orthopedic oncology market. Our company is focused and dedicated to bringing solutions to this group of surgeons and patients that will address the significant unmet need that exists. Today is a very important milestone for our company and we look forward to executing on our robust pipeline of innovation."
Dr. Steven Gitelis, Professor and Vice Chairman, Department of Orthopedic Surgery, at Rush University Medical Center and an Onkos Surgical Surgeon Advisory Board member said, "Tumor surgery is often personalized as each patient presents differently. When replacing bone with an implant, ELEOS provides the flexibility and modularity a surgeon needs for these complex cases. The ELEOS system is a long term reconstructive option for oncology patients. Our patient population is unique and we need a company like Onkos to provide innovation where we have our most challenging need."
"We will continue to leverage ELEOS and our 3D printing capabilities to drive our innovation initiatives," said Treacy. "ELEOS will be a foundational system for the company and we are planning for a full launch in the first quarter of 2017."
About Onkos Surgical
Based in Parsippany, NJ., Onkos Surgical is a privately held surgical oncology company founded in 2015. Onkos Surgical believes surgical oncology deserves attention, focus and innovation. Through dedication and strategic partnerships, Onkos Surgical will advance surgical oncology solutions and will advocate for and support the surgeons and caregivers that dedicate their lives to the surgical treatment of cancer.
For more information, visit www.onkossurgical.com
About 1315 Capital
1315 Capital is a private investment firm that provides expansion and growth capital to commercial-stage specialty pharmaceutical, medical technology, and healthcare service companies. We target markets where high-quality management teams can rapidly scale platform companies into large and important businesses that positively impact patients, physicians, and the broader healthcare system.
For more information, visit www.1315capital.com
Source: Onkos Surgical
Issuer of this News Release is solely responsible for its
Please address inquiries directly to the issuing company.